BioLineRx Ltd. (BLRX)
3.257
+0.04
(+1.15%)
USD |
NASDAQ |
Dec 04, 16:00
3.38
+0.12
(+3.78%)
Pre-Market: 08:21
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 14.17M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -69.85% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 0.8953 |
| Price to Book Value | 0.7256 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.5825 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 98.76% |
Profile
| BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel. |
| URL | http://www.biolinerx.com |
| Investor Relations URL | http://ir.biolinerx.com/phoenix.zhtml?c=208785&p=irol-IRHome |
| HQ State/Province | HaMerkaz |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 31, 2026 (est.) |
| Last Earnings Release | Nov. 24, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel. |
| URL | http://www.biolinerx.com |
| Investor Relations URL | http://ir.biolinerx.com/phoenix.zhtml?c=208785&p=irol-IRHome |
| HQ State/Province | HaMerkaz |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | Mar. 31, 2026 (est.) |
| Last Earnings Release | Nov. 24, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |